S. Theile

发表

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

S. Brunak, I. Svane, B. Jensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study

L. Sengeløv, M. Mikkelsen, D. Nielsen, 2022, The oncologist.

A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

M. Heuser, F. Thol, A. Ganser, 2020, British journal of haematology.

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

P. Vilmann, O. Nielsen, J. T. Bjerrum, 2022, Journal for ImmunoTherapy of Cancer.

Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study

M. Heuser, F. Thol, C. Bokemeyer, 2015 .

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine

D. Nielsen, B. Jensen, I. Kümler, 2019, Cancer Chemotherapy and Pharmacology.

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).

M. Donia, I. Svane, E. Høgdall, 2022, European journal of cancer.

Genomic landscape of treatment refractory metastatic colorectal cancer

E. Høgdall, B. Jensen, L. Klarskov, 2021, Acta oncologica.

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)

C. Hansen, B. Jensen, J. Johansen, 2022, Pharmaceutics.

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.

C. Bokemeyer, J. Mann, A. Stein, 2020, Current cancer drug targets.

Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.

B. K. Jensen, D. Nielsen, B. Jensen, 2019, Breast.

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

D. Nielsen, E. Høgdall, B. Jensen, 2018, Cancer Chemotherapy and Pharmacology.

Effects of a 12-week multimodal exercise intervention among older patients with advanced cancer - results from a randomized controlled trial.

M. Jarden, J. Johansen, A. Vinther, 2021, The oncologist.

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

I. Svane, G. Persson, H. Hendel, 2023, BMJ Open.

Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

M. Heuser, F. Thol, C. Bokemeyer, 2016 .

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy

A. Johansen, D. Nielsen, S. Theile, 2023, Frontiers in immunology.

Cancer patients, physicians, and nurses differ in their attitudes toward the decisional role in do-not-resuscitate decision-making

S. Dalton, D. Nielsen, C. Dehlendorff, 2020, Supportive Care in Cancer.